P1, N=95, Terminated, Five Prime Therapeutics, Inc. | Phase classification: P1a/1b --> P1 | Completed --> Terminated; The Sponsor terminated the study for reasons unrelated to safety.
P1a/1b, N=95, Completed, Five Prime Therapeutics, Inc. | Active, not recruiting --> Completed | N=278 --> 95 | Trial completion date: Jan 2022 --> May 2021 | Trial primary completion date: Jan 2022 --> May 2021
almost 3 years ago
Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)